DalsnaFinance › Analyst accuracy › William Blair › CYTK target
William Blair initiates Cytokinetics stock coverage with outperform rating
set a price target of $101 per share based on a discounted cash flow valuation.
A fact about what William Blair published, as reported by Investing.com, not a recommendation from Dalsna Finance; William Blair is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.